See more : Comer Industries S.p.A. (COM.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Neo-Neon Holdings Limited (911868.TW) Income Statement Analysis – Financial Results
- Paramount Cosmetics (India) Limited (PARMCOS-B.BO) Income Statement Analysis – Financial Results
- Futaba Corporation (FUBAF) Income Statement Analysis – Financial Results
- Innovative Tech Pack Limited (INNOVTEC.BO) Income Statement Analysis – Financial Results
- Hanmi Pharm. Co., Ltd. (128940.KS) Income Statement Analysis – Financial Results
Intra-Cellular Therapies, Inc. (ITCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | 0.00 | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
| Cost of Revenue | 33.75M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
| Gross Profit Ratio | 92.73% | 91.79% | 90.17% | 91.59% | -687.16% | 0.00% | -32,205.56% | -28,273.44% | -52.82% | -3,576.82% | -741.34% | -396.68% |
| Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| General & Administrative | 317.66M | 272.98M | 190.11M | 150.06M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Selling & Marketing | 92.20M | 85.80M | 82.50M | 36.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Other Expenses | 0.00 | -1.18M | -2.10M | -282.23K | 0.00 | 0.00 | -245.84K | -330.70K | -60.71K | -29.76K | 0.00 | 0.00 |
| Operating Expenses | 590.01M | 492.32M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
| Interest Expense | 0.00 | 7.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.78K | 0.00 | 7.07K | 612.96K | 193.50K |
| Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |
| EBITDA | -158.85M | -262.97M | -285.16M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| EBITDA Ratio | -34.21% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -40,203.17% | -34,872.43% | -115,815.85% | -5,314.87% | -957.76% | -523.31% |
| Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
| Operating Income Ratio | -34.32% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -41,832.65% | -35,759.96% | -115,815.85% | -5,367.52% | -959.69% | -526.09% |
| Total Other Income/Expenses | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.90M | 1.02M | 296.86K | -583.35K | -154.50K |
| Income Before Tax | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Income Before Tax Ratio | -29.94% | -102.86% | -347.73% | -1,007.48% | -243,711.05% | 0.00% | -40,203.17% | -34,883.55% | -114,696.75% | -5,316.09% | -981.01% | -531.04% |
| Income Tax Expense | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
| Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Net Income Ratio | -30.08% | -102.86% | -347.73% | -1,007.54% | -243,713.69% | 0.00% | -39,771.64% | -35,205.79% | -114,698.50% | -5,316.37% | -981.67% | -532.10% |
| EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| Weighted Avg Shares Out | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Weighted Avg Shares Out (Dil) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
Source: https://incomestatements.info
Category: Stock Reports